SALSA MLPA P040 CLL probemix - 100 reactions

application: Chronic Lymphocytic Leukemia (CLL)
region: Various Detailní informace

Cena s DPH € 1 147.08
Cena bez DPH € 948.00
 100 react
Dostupnost Skladem
Kód produktu P040-100R

Nejnovější informace o produktu naleznete exklusivně na stránkách výrobce MRC-Holland www.mlpa.com (nové okno)

Detailní popis SALSA MLPA P040 CLL probemix - 100 reactions

P040-100R SALSA MLPA P040 CLL probemix – 100 rxn

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) is the most common hematological neoplasm in Western countries and results in the progressive accumulation of CD5(+)  CD23(+) B lymphocytes that appear morphologically mature but are functionally incompetent in bone marrow, blood, spleen and lymph nodes of the affected person. Chromosomal translocations are rare events in B-CLL. Copy number changes of certain chromosomal regions are however frequent. Some of these have been found to be highly prognostic markers of this disease.

SALSA® MLPA® probemixes P037 and P038 contain probes for several genomic regions that are recurrently imbalanced in B  cell CLL. The P040 probemix contains a selection of targeted genes and regions from P037 and P038.

The P040 CLL MLPA probemix can be used to determine the loss of TP53 on 17p13 (6 probes), the RB1 / DLEU / MIRN15A-16 region on 13q14 (10 probes), the ATM gene on 11q22 (7 probes) as well the presence of trisomy 12 (11 probes) in DNA samples obtained from chronic lymphocytic leukemia. In addition, 13 reference probes on various other chromosomes are present. For each region to be analysed, several probes are present. This is necessary for correct analysis of samples containing lower (30-60 %) percentages of tumour cells. Please, note that diploid and tetraploid cells cannot be distinguished by MLPA. Only changes in relative copy number of the sequences detected by the probes will result in a changed peak MLPA pattern.

This SALSA® MLPA® probemix is designed to detect copy number changes of one or more sequences in the above mentioned genes and chromosomal regions in a DNA sample. Heterozygous deletions of recognition sequences should give a 35-50 % reduced relative peak area of the amplification product of that probe. Note that a mutation or polymorphism in the sequence detected by a probe can also cause a  reduction in relative peak area, even when not located exactly on the ligation site! In addition, some probe signals are more sensitive to sample purity and small changes in experimental conditions. Therefore, deletions and duplications detected by MLPA should always be confirmed by other methods. Not all deletions and duplications detected by MLPA will be pathogenic; users should always verify the latest scientific literature when interpreting their findings.

Kontaktujte nás

BIOGEN PRAHA s.r.o.
Ke sv. Izidoru 2293/4A
140 00 PRAHA 4

Tel.: +420 241 401 693
Fax: +420 241 401 694
E-mail: biogen@biogen.cz

Novinky na e-mail

Vaše osobní údaje nejsou nikde zveřejňovány a splňují požadavky GDPR.